Jiangsu Hengrui Medicine Company Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Bostik Sa

Kla Corporation

Shanghai Jiaotong University

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Shanghai Normal University

Changzhou Hansoh Pharmaceutical Co., Ltd.

Shanghai Xiyuan Biotechnology Co., Ltd.

Hansoh (shanghai) Healthtech Co., Ltd.

Xin Ye

Weikang Tao

Lianshan Zhang

Xiangdong Qu

Lei Zhang

Piaoyang Sun

Qiyue Hu

Guoqing Cao

Jijun Yuan

Dongbing Cui

Li Yang

Ting Ting Zhang

Liuqing Yang

Xiaohua Wang

Jinming Gu

Zhibin Xu

Jufang Lin

Daniel C Wack

Rui-Fang Shi

Damon Floyd Kvamme

Yuanfeng Wang

Hu Ge

Jiahua Jiang

Cheng Liao

Shaoyu Xu

Xiaoling Gu

Kang Wei

Xinlin Wei

Zupeng Xu

Peipei He

Genta Okazaki

Danfeng Li

Lizeng Cheng

Sseunhyeun Jo

Kan Chen

Bei Yuan

Provided are an anti-PD-1 antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. Specifically, provided are a humanized anti-PD-1 antibody containing a specific CDR region and an antigen-binding fragment thereof, a pharmaceutical composition containing the anti-PD-1 antibody and the antigen-binding fragment thereof, and a used thereof as medicament. In particular, provided is a use of the humanized anti-PD-1 antibody in the preparation of the medicament for treating PD-1 associated diseases or disorders.

Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof

The invention relates to a hot-melt pressure sensitive adhesive composition comprising at least one styrenic block copolymer, at least one tackifying resin, at least one mineral oil and from 4 to 15% by weight of at least one wax selected from the group consisting of paraffin waxes, Fischer-Tropsch waxes, ethylene-vinyl acetate waxes and any mixture thereof, based on the total weight of the hot-melt pressure sensitive adhesive composition. The invention also relates to an article comprising a surface coated with such a hot-melt pressure sensitive adhesive composition, to a use of such a hot-melt pressure sensitive adhesive composition and to a process for preparing such a hot-melt pressure sensitive adhesive composition.

Low tack hot-melt pressure sensitive adhesives

The invention relates to a hot melt adhesive composition comprising a polymer component, the polymer component comprising at least one styrene-butadiene-styrene block copolymer P having a styrene content from 35 to 50% by weight: a styrene-butadiene diblock content from 50 to 80% by weight; and a viscosity of a 15% by weight toluene solution at 25° C. of 20 to 40 mPa·s, and at least one styrene block copolymer other than a styrene-butadiene-styrene block copolymer, wherein said styrene-butadiene-styrene block copolymer P is at a content from 10 to 40% by weight relative to the total weight of the polymer component. The invention also relates to the use of said composition as an adhesive for bonding two substrates, and to articles comprising at least one interior or exterior surface coated with said composition.

Hot melt adhesive composition having improved wet bonding strength

The present invention provides an anti-ox40 antibody, an antigen-binding fragment thereof, and the pharmaceutical use. Further, the present application provides a chimeric antibody and a humanized antibody, the chimeric antibody and the humanized antibody comprising a CDR region from the anti-OX40 antibody and the antigen-binding fragment thereof, and also provides a pharmaceutical composition comprising the anti-OX40 antibody and the antigen-binding fragment thereof, and the use thereof as a drug for treating cancers.

Anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical use

An interleukin 15 (IL-15) protein complex is provided. The IL-15 protein complex includes soluble fusion proteins (I) and (II), wherein the fusion protein (I) is an IL-15 polypeptide or a functional fragment thereof, and the soluble fusion protein (II) is an IL-15R&#x3b1; polypeptide or a functional fragment thereof. The soluble fusion protein (I) has at least one amino acid residue mutated to a cysteine (Cys) residue, which pairs with a corresponding mutated Cys residue on the soluble fusion protein (II), or vice versa, to form one or more disulfide bonds. The IL-15 protein complex can be used for tumor therapy.

Interleukin 15 protein complex and use thereof

A B7-H3 antibody, an antigen-binding fragment thereof and a medical use thereof are provided. Furthermore, a pharmaceutical composition containing the B7-H3 antibody or antigen-binding fragment thereof, and the use thereof as a medicament are provided. In particular, a use of a human B7-H3 antibody or antigen-binding fragment thereof for the manufacture of a medicament for the treatment of a B7-H3-associated disease or condition are described.

B7-H3 antibody, antigen-binding fragment thereof and medical use thereof

The present disclosure provides a functional beverage of dark tea with zero energy for reducing weight and lipid and a preparation method thereof, and relates to the technical field of processing health-promoting beverage. The functional beverage includes 1.5-3.5 parts of dark tea, 0.3-0.7 parts of mulberry leaf, 0.1-0.5 parts of lotus leaf, 0.1-0.3 parts of stevia leaf, and 95.4-97.4 parts of purified water. The preparation process thereof includes treatment of raw materials, circulatory microwave extraction, static settlement, membrane ultrafiltration, and ultra-high temperature instantaneous sterilization (UHT). Compared with the prior art, the functional beverage uses purely natural herb plants without any additives. The obtained product has zero sugar while has the effects of quenching thirst and reducing weight and lipid. Key technologies such as integrated formula, circulatory microwave extraction, and membrane ultrafiltration enable the best flavor and efficacy of the beverage.

Preparation method for functional beverage of dark tea with zero energy for reducing weight and lipid

The present invention provides a human PD-1 antibody, an antigen-binding fragment thereof, and medical use thereof, and further provides a chimeric antibody and humanized antibodies comprising a complementarity-determining region (CDR) of the antibody, a pharmaceutical composition comprising the human PD-1 antibody and the antigen-binding fragment thereof, and use of the antibody in preparing medicines for treating diseases or disorders.

PD-1 antibody, antigen-binding fragment thereof, and medical application thereof

An inspection system includes an illumination source configured to generate extreme ultraviolet (EUV) light, illumination optics to direct the EUV light to a sample within a range of off-axis incidence angles corresponding to an illumination pupil distribution, collection optics to collect light from the sample in response to the incident EUV light within a range of collection angles corresponding to an imaging pupil distribution, and a detector configured to receive at least a portion of the light collected by the collection optics. Further, a center of the illumination pupil distribution corresponds to an off-axis incidence angle along a first direction on the sample, and at least one of the illumination pupil distribution or the imaging pupil distribution is non-circular with a size along the first direction shorter than along a second direction perpendicular to the first direction.

Inspection system with non-circular pupil

Interleukin 15 protein complex

The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and a medicinal application thereof. Provided in the invention is a chimeric antibody and a humanized antibody, both comprising a CDR of the PCSK9 antibody, and a pharmaceutical composition comprising the PCSK9 antibody and an antigen-binding fragment thereof, and an application of the PCSK9 antibody as a lipid-lowering agent. The invention specifically relates to an application of a humanized PCSK9 antibody for preparing a pharmaceutical drug to treat a PCSK9-induced disease or symptom.

PCSK9 antibody, antigen-binding fragment thereof, and medical application thereof

Provided is an IL-15 heterodimeric protein, such as an IL-15/IL-15R&#x3b1; heterodimeric protein. The IL-15 heterodimeric protein contains protein (I) and protein (II). Protein (I) is recombinantly produced by combining IL-15 or a variant thereof with a first Fc variant, and protein (II) is a second Fc variant, or recombinantly produced by combining IL-15R&#x3b1; or a variant thereof with a second Fc variant. The first Fc variant and the second Fc variant are preferably linked via a 'Knob-into-Hole' mode. Also provided are methods of using the IL-15 heterodimeric proteins to modulate an immune response. The provided IL-15 heterodimeric proteins have significant anti-tumor activity, better biological activity and prolonged in vivo half-life compared to the IL-15 molecule alone.

IL-15 heterodimeric protein and uses thereof

Growing community of inventors

Shanghai, China

Xin Ye